Charles Rhyee
Stock Analyst at TD Cowen
(2.01)
# 3,046
Out of 5,139 analysts
72
Total ratings
41.67%
Success rate
-6.58%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ICLR ICON Public Limited Company | Upgrades: Buy | $183 → $120 | $98.41 | +21.94% | 7 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Upgrades: Hold | $462 → $419 | $446.44 | -6.15% | 7 | Feb 18, 2026 | |
| CI The Cigna Group | Maintains: Buy | $333 → $338 | $285.92 | +18.21% | 2 | Feb 9, 2026 | |
| MCK McKesson | Maintains: Buy | $1,000 → $1,012 | $937.14 | +7.99% | 5 | Feb 5, 2026 | |
| IQV IQVIA Holdings | Maintains: Hold | $215 → $245 | $169.36 | +44.66% | 3 | Jan 22, 2026 | |
| FTRE Fortrea Holdings | Maintains: Hold | $7 → $15 | $11.01 | +36.24% | 4 | Jan 22, 2026 | |
| MDLN Medline | Initiates: Buy | $46 | $47.60 | -3.36% | 1 | Jan 12, 2026 | |
| GDRX GoodRx Holdings | Maintains: Buy | $7 → $6 | $2.36 | +154.24% | 8 | Nov 10, 2025 | |
| CRL Charles River Laboratories International | Maintains: Buy | $205 → $197 | $164.24 | +19.95% | 6 | Nov 10, 2025 | |
| COR Cencora | Maintains: Buy | $350 → $400 | $359.11 | +11.39% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $100 | $77.32 | +29.33% | 1 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $183 → $225 | $222.76 | +1.01% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $27 | $35.66 | -24.28% | 2 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $297 → $380 | $182.57 | +108.14% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $9 → $8 | $4.88 | +63.93% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $4.83 | +3.52% | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $5.74 | +771.08% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $11.22 | +399.11% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $11.43 | +2,349.69% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $2.77 | +1,705.05% | 2 | Jun 21, 2022 |
ICON Public Limited Company
Feb 18, 2026
Upgrades: Buy
Price Target: $183 → $120
Current: $98.41
Upside: +21.94%
Medpace Holdings
Feb 18, 2026
Upgrades: Hold
Price Target: $462 → $419
Current: $446.44
Upside: -6.15%
The Cigna Group
Feb 9, 2026
Maintains: Buy
Price Target: $333 → $338
Current: $285.92
Upside: +18.21%
McKesson
Feb 5, 2026
Maintains: Buy
Price Target: $1,000 → $1,012
Current: $937.14
Upside: +7.99%
IQVIA Holdings
Jan 22, 2026
Maintains: Hold
Price Target: $215 → $245
Current: $169.36
Upside: +44.66%
Fortrea Holdings
Jan 22, 2026
Maintains: Hold
Price Target: $7 → $15
Current: $11.01
Upside: +36.24%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $46
Current: $47.60
Upside: -3.36%
GoodRx Holdings
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.36
Upside: +154.24%
Charles River Laboratories International
Nov 10, 2025
Maintains: Buy
Price Target: $205 → $197
Current: $164.24
Upside: +19.95%
Cencora
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $359.11
Upside: +11.39%
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $77.32
Upside: +29.33%
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $222.76
Upside: +1.01%
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $35.66
Upside: -24.28%
Oct 7, 2025
Upgrades: Buy
Price Target: $297 → $380
Current: $182.57
Upside: +108.14%
Oct 31, 2024
Maintains: Hold
Price Target: $9 → $8
Current: $4.88
Upside: +63.93%
May 3, 2023
Maintains: Outperform
Price Target: $4 → $5
Current: $4.83
Upside: +3.52%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $5.74
Upside: +771.08%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $11.22
Upside: +399.11%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $11.43
Upside: +2,349.69%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $2.77
Upside: +1,705.05%